Hypometabolism as a therapeutic target in Alzheimer's disease.
The pathology of Alzheimer's disease (AD) is characterized by cerebral atrophy in frontal, temporal, and parietal regions, with senile plaques, dystrophic neurites, and neurofibrillar tangles within defined areas of the brain. Another characteristic of AD is regional hypometabolism in the brain. This decline in cerebral glucose metabolism occurs before pathology and symptoms manifest, continues as symptoms progress, and is more severe than that of normal aging. Ketone bodies are an efficient alternative fuel for cells that are unable to metabolize glucose or are 'starved' of glucose. AC-1202 is designed to elevate serum ketone levels safely. We previously showed that treatment with AC-1202 in patients with mild-to-moderate AD improves memory and cognition. Treatment outcomes were influenced by apolipoprotein E genotype status. These data suggest that AC-1202 may be an effective treatment for cognitive dysfunction by providing an alternative substrate for use by glucose-compromised neurons.
Costantini
Lauren C
LC
Accera Inc., Interlocken Crescent, Broomfield, CO 80021, USA. lcostantini@accerapharma.com
Barr
Linda J
LJ
Vogel
Janet L
JL
Henderson
Samuel T
ST
D000544:Alzheimer Disease / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D000818:Animals; D001057:Apolipoproteins E / Q000378:metabolism; D001921:Brain / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D003071:Cognition / Q000187:drug effects; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D007657:Ketone Bodies / Q000097:blood / Q000378:metabolism; D008568:Memory / Q000187:drug effects; D014280:Triglycerides / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use
C538853:AC-1202; D001057:Apolipoproteins E; D007657:Ketone Bodies; D014280:Triglycerides; D005947:Glucose